- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
In re Fenofibrate Patent Litig.
4.71/1 does not fall “between 5/1 and 15/1,” particularly when the range was limited during prosecution to avoid prior art.
April 17, 2013
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: In re Fenofibrate Patent Litig., Case No. 11 MDL 2241, 2013 U.S. Dist. LEXIS 21165 (S.D.N.Y. Jan. 4, 2013) (Rakoff, J.)
Drug Product and Patent(s)-in-Suit: Antara® (fenofibrate); U.S. Patent Nos. 7,101,574 (“the ’574 patent”) and 7,863,331 (“the ’331 patent”)
Nature of the Case and Issue(s) Presented: In a prior Order, the district court granted Mylan’s motion for summary judgment of non-infringement. The disputed claim element required a particular ratio of fenofibrate to binding cellulose derivative of “between 5/1 and 15/1.” The district court found that Mylan’s proposed product had an undisputed ratio of 4.71/1, falling outside the claim limitation. Lupin sought a preliminary injunction to preclude Mylan from introducing its generic product to the market. Lupin argued that the district court erred because it relied on cases that were factually opposite of the present case. In particular, Lupin argued that it would show on appeal that the claimed range would include Mylan’s proposed generic product because a person of ordinary skill would have rounded the ratio to the first integer. The district court denied Lupin’s motion for a preliminary injunction.
Why Mylan Prevailed: The court held thatLupin could not show a likelihood of success on the merits. In particular, the district court noted that Lupin merely asserted the arguments it presented in opposition to summary judgment in its motion for preliminary injunction. The district court noted that there were factual differences between the present case and the cited cases, but those differences did not change the common sense patent law basics that the word “between” means “in the time, space or interval that separates.” Moreover, Lupin failed to recognize that the ratios limitation were added to distinguish the invention from the prior art. This limited the scope of the claim and Lupin could not reclaim substance that it gave up in prosecution.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.